Joint Corp Q2 Revenue Beats, Reiterates 2026 Outlook
JYNT is trading near its 52-week low of $7.5 (9.6% above the low).
Summary
Joint Corp reported Q2 revenue of $15.2M, beating the $14.57M consensus, with EPS of $0.05. The company reiterated its 2026 system-wide sales guidance of $519M-$552M and adjusted EBITDA of $12.5M-$13.5M. New franchised clinic openings are now expected at 22-26, excluding refranchised clinics. The results reflect the ongoing shift to a pure-play franchisor model, which improved patient retention and operating efficiency. The company also repurchased $677K in shares and completed three regional developer territory buybacks. This follows a 10% owner's $1.27M stock purchase in May and an activist stake increase to 27.9% earlier this year, signaling insider and investor confidence in the turnaround.
At the time of this announcement, JYNT was trading at $8.22 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $117.2M. The 52-week trading range was $7.50 to $11.26. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.